"Univercell-Biosolutions technology provides an opportunity to reduce animal testing in the research and development process, while providing more reliable prediction of clinical effects through the use of human cells.”

Michel Puceat, PhD, Chairman of the Scientific Advisory Board, Univercell-Biosolutions

MESOPURE®

MESOPURE®: An original approach aimed at bridging the gap between preclinical and clinical development

While most existing protocols are based on the results of fundamental research, Univercell-Biosolutions’ scientific innovation has been clinically oriented from the outset. This original approach beneficiates of skills required for a clinical application which today represents key advantages for in vitro applications.

Univercell-Biosolutions’ world-leading MESOPURE® technology yields >99% pure cardiovascular progenitors suitable for producing enriched populations of human cardiomyocytes  and endothelial cells.

Univercell-Biosolutions uses MESOPURE® technology to develop iPS cell-derived human cardiomyocytes (CM-ONE®) and iPS cell-derived human endothelial cells (ED-ONE®) with the homogeneity and maturity required by the pharmaceuticals industry.

From pluripotent stem cells (hES or hiPS) to early cardiovascular progenitor cells


Mesopure® propose a unique  access to millions of  human heart
and endothelial cells to optimize the drug discovery process

Key advantages of MESOPURE® technology:

  • Homogeneity: Sorting method yielding >99% pure cell populations of cardiovascular progenitors
  • Reproducibility: Totally Reproducible and standardized technology
  • Regulatory: GMP compatibility